Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Dow
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,309,966

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,309,966
Title:Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
Abstract: The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated cancer. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist.
Inventor(s): Sibilia; Maria (Vienna, AT)
Assignee: Medizinische Universitat Wien (Vienna, AT)
Application Number:15/312,252
Patent Claims:1. A method of testing a subject for the need of treatment of an inflammation-associated cancer, wherein the subject has or is suspected of having said cancer, and wherein the inflammation-associated cancer is hepatocellular carcinoma or an inflammation-associated intestinal cancer, the method comprising the steps of: (a) obtaining a sample from the subject that comprises a myeloid cell population, wherein the myeloid cells in the myeloid cell population are CD68-positive macrophage cells and/or Kupffer cells and are from within said cancer or from the tissue adjacent to said cancer; (b) testing the myeloid cell population to identify that portion of myeloid cells that detectably express EGFR, wherein greater than 5% of myeloid cells in the myeloid cell population detectably express EGFR; and (c) treating the subject by administering a therapeutically effective amount of an EGFR inhibitor/antagonist to the subject.

2. The method of claim 1, wherein the subject is a human.

3. The method of claim 1, wherein greater than 10% of myeloid cells in the myeloid cell population detectably express EGFR.

4. The method of claim 3, wherein greater than 20% of myeloid cells in the myeloid cell population detectably express EGFR.

5. The method of claim 4, wherein greater than 30% of myeloid cells in the myeloid cell population detectably express EGFR.

6. The method of claim 1, wherein the sample is a cancer tissue biopsy sample.

7. The method of claim 1, wherein the myeloid cells are CD68-positive macrophage cells.

8. The method of claim 1, wherein the inflammation-associated cancer is hepatocellular carcinoma.

9. The method of claim 1, wherein the sample is a liver tissue sample.

10. The method of claim 1, wherein the myeloid cells are Kupffer cells.

11. The method of claim 1, wherein the inflammation-associated cancer is colorectal cancer.

12. The method of claim 11, wherein the sample is a colorectal tissue sample or a colorectal polyp.

13. The method of claim 1, wherein the myeloid cells are identified by determining a level of translation of EGFR therein.

14. The method of claim 13, wherein the level of translation is determined using an immunohistochemical method, an enzyme-linked immunosorbent assay, or a radioimmunoassay.

15. The method of claim 1, wherein the EGFR inhibitor/antagonist is selected from the group consisting of gefitinib, erlotinib, lapatinib, afatinib, neratinib, ABT-414, dacomitinib, AV-412, PD 153035, vandetanib, PKI-166, pelitinib, canertinib, icotinib, poziotinib, BMS-690514, CUDC-101, AP26113, XL647, cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, and a pharmaceutically acceptable salt thereof.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14169512May 22, 2014
PCT Information
PCT FiledMay 21, 2015PCT Application Number:PCT/EP2015/061220
PCT Publication Date:November 26, 2015PCT Publication Number:WO2015/177266

Details for Patent 10,309,966

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Medizinische Universitat Wien (Vienna, AT) 2034-05-22 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Medizinische Universitat Wien (Vienna, AT) 2034-05-22 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Medizinische Universitat Wien (Vienna, AT) 2034-05-22 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Medizinische Universitat Wien (Vienna, AT) 2034-05-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
Boehringer Ingelheim
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.